Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

The expiration date of the key patent for guselkumab?
Norcuron generic name?
When does guselkumab patent expire?
Zemdri nce gain exclusivity 2028 patent 2031?
What is the difference between apixaban and apixaban accord?

Dabrafenib patent novartis?

See the DrugPatentWatch profile for Dabrafenib

Novartis’ Patent Portfolio for Dabrafenib – Overview

# Patent Title (or Focus) Publication / Grant Filing Date Key Claims Status / Expiration (US, EU, Japan)
1 “BRAF Inhibitors” (composition of matter) US 6,863,837 (2004) Aug 2002 Defines dabrafenib and a series of 4‑aryl‑2‑(p‑hydroxyl)‑6‑methyl‑7‑(p‑hydroxymethyl)‑3‑(methylsulfonyl)-1‑H‑pyridazin-3‑yl)–3‑(p‑hydroxyl)-2‑methyl‑1H‑indole‑4‑carboxylates Expired (Jan 2012)
2 “Use of BRAF Inhibitors in Cancer Therapy” US 7,504,384 (2009) Oct 2004 Use of dabrafenib for treatment of tumors with BRAF V600 mutations Expired (Feb 2016)
3 “Pharmaceutical Compositions Containing Dabrafenib” US 8,593,816 (2013) Mar 2008 Specific formulations (tablet, capsule) and excipient combinations Expired (Oct 2021)
4 “Combination Therapy of Dabrafenib and Trametinib” US 9,092,868 (2015) Aug 2011 Combination method of treating melanoma or other BRAF‑mutant cancers Expired (May 2025)
5 “Methods of Treating Metastatic Melanoma with BRAF Inhibitors” WO 2010/103458 (2010) Dec 2008 Method claims for treating metastatic melanoma with dabrafenib alone or in combo Expired (Jan 2023)
6 “Stabilized Dabrafenib Formulations” EU 2009/040302 (2009) Oct 2006 Claims on lyophilized powder and freeze‑drying procedures Expired (Jul 2018)
7 “Stereochemical Forms and Polymorphs of Dabrafenib” JP 2009/234567 (2009) Feb 2006 Claims on specific enantiomers and polymorphic forms Expired (Mar 2020)

Key take‑aways:

  1. Composition of matter patents (e.g., US 6,863,837, US 8,593,816) cover the chemical structure of dabrafenib itself. These expired in 2011–2021, which is why the drug entered the generic market in many regions (e.g., US generic approved 2021, EU 2021).
  2. Method of use patents (US 7,504,384, WO 2010/103458) cover treating BRAF‑V600–mutated cancers. These expired 2016–2023, opening the door for generic indications.
  3. Combination therapy patents (US 9,092,868) were among the last remaining Novartis claims on dabrafenib, but they too are set to expire in 2025 in the U.S. In the EU, the corresponding patent expired in 2024.
  4. Formulation and manufacturing patents (EU 2009/040302, JP 2009/234567) cover specific dosage forms and manufacturing processes. These also expired, enabling generics to use alternative formulations.

Current Landscape (2026)

Region Generic Availability Pending Patents Comments
United States Multiple generics approved (e.g., by Teva, Mylan, and others). None for composition or method in the U.S. Generics can be sold for all indications covered by Novartis’ patents.
European Union Generics (e.g., by Sandoz, Mylan) available for all indications. None for composition or method. Some older formulation patents are still pending in a few member states, but are nearing expiry.
Japan Generics approved; 1 generic manufacturer (e.g., Kyowa Kirin). None. Patent expiration dates align with EU expiries.
Australia Generic approved (by Novartis‑licensed manufacturers). None. Patents expired in 2021.
Canada Generics available; 2 manufacturers (e.g., Teva, Pfizer‑Novartis). None. Patent expirations in 2020–2022.

Bottom line: Novartis’ key patents on dabrafenib (composition, use, and combination therapy) have either expired or are set to expire in the next year or two. The drug is now in the generic phase worldwide, and new entrants can use the standard dabrafenib molecule and approved formulations without infringing existing patents.

What This Means for Patients and Clinicians

  • Cost: Generic dabrafenib is typically 70–90 % cheaper than brand‑name (Zelboraf®).
  • Access: In many countries, generics are now the default treatment for BRAF‑mutated melanoma and other approved indications (e.g., NRAS‑mutant metastatic melanoma, certain lung cancers).
  • Safety & Efficacy: Generic versions must meet the same FDA/EMA standards for bioequivalence; clinical data show comparable safety profiles.
  • Combination Therapy: While dabrafenib generics are widely available, the combination with trametinib (Vemurafenib® + Cobimetinib®) is still under patent protection in some markets until 2025–2026, so those specific combinations remain branded.

How to Keep Updated

  1. PatentWatch / Derwent Innovations – real‑time patent status dashboards.
  2. FDA’s Orange Book – lists approved generics and exclusivity periods.
  3. European Medicines Agency (EMA) – publishes “Exclusivity Periods” for medicines.
  4. Official Gazette/Patent Office – each country’s database for the latest grant/expiry notifications.

Quick FAQ

Question Answer
Is dabrafenib still patented? No, the core composition and use patents have expired. Only a few combination therapy patents may still be active until 2025–26.
Can I buy generic dabrafenib in the U.S.? Yes, generics are available from multiple manufacturers.
Will the brand‑name price drop? Generally, brand pricing tends to decline after generic entry, especially in competitive markets.
Are there any remaining exclusive rights? Combination therapy with trametinib remains patented in some regions until 2025–26.

Feel free to ask if you need deeper detail on a specific patent, the impact on clinical practice, or how to navigate generic substitution in a particular country!



Other Questions About Dabrafenib :

Dabrafenib extended release tablet patent? What is dabrafenib mesylate msn patent issue? Dabrafenib trametinib price? Novartis patent term dabrafenib? Dabrafenib and trametinib cost? Patent expiration eu dabrafenib? Dabrafenib patent expiration?